RecQ mediated genome instability 2 (): a potential prognostic and immunological biomarker for pan-cancers.

Background: RecQ mediated genome instability 2 () is an essential component of the BLM-TopoIIIa-RMI1- (BTR) complex. However, the mysterious veil of the potential immunological relationship of in tumorigenesis and development has not been revealed.

Methods: We conducted the differential expression (DE) analysis of the in pan-cancer using data onto Oncomine, TIMER, and GEPIA databases. Afterward, survival analysis and clinical-stage correlation analysis were performed via the TCGA database. Subsequently, we used R software to further explore the relationship between the expression level of and tumor mutation burden (TMB), microsatellite instability (MSI), tumor microenvironment (TME), tumor immune-infiltrated cells (TILs), immune checkpoints (ICP), mismatch repairs (MMRs) -related genes, m6A-related genes, DNA methylation-related genes. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional networks were also performed for annotation via gene set enrichment analysis (GSEA).

Results: The expressed remarkably high in most cancer types compared to cancer adjacent normal tissues ( < 0.05). High expression of was linked to unfavorable prognosis and advanced stage of disease, especially in LIHC and PAAD. expression was related to TMB in 16 cancer types and MSI in 8 cancer types. Furthermore, it is significant positive correlations between and stromal and immune cells, ICP-related genes, MMRs-related genes, m6A-related genes, and DNA methylation-related genes. Finally, GSEA analysis revealed that was engaged in a variety of signaling pathways in pan-cancers.

Conclusions: may serve as a potential biological target and probably assume a crucial part in tumorigenesis and progression.